Chunbo천보

Chunbo's trailing revenue is holding up, but losses are deep and the share price has fallen about 45% over the past year.

Chunbo makes specialty chemicals for display, battery and pharmaceutical customers. Over the twelve months to H1 2026 it booked about ₩157B of revenue, an operating loss of about ₩9.2B and a net loss of about ₩64.6B, with borrowings of about ₩406B against cash of about ₩16B. The shares closed at ₩32,200 on 2026-10-23, well below the 52-week high of ₩80,600.

What stands out

• Revenue fell in 2024 (-20.7%) and 2023 (-44.4%) and again in 2025 (-7.6%) to about ₩134B, after being ₩329B in 2022.
• 2025 showed a small operating profit of about ₩3.7B, but the net loss was about ₩57.8B, so below-operating-line costs are large.
• Trailing free cash flow was negative at about -₩44B, and liabilities are 88.2% of equity.
• Price-to-book is 0.9 versus 7.8 at end-2022, and no dividend is paid (yield 0%).
• Filings in June to August 2026 include a collateral provision for a third party and a conversion price adjustment; the data does not explain their size or effect.
• Foreign ownership rose from 3.7% to 4.3% over 60 days, while institutions net sold about ₩1.4B and retail net bought about ₩1.9B over 20 days.

What to watch

• Next results and the full-year 2026 outcome, since trailing operating income is negative.
• Debt levels (₩406B borrowings) and refinancing, plus any further collateral or conversion-related filings.
• No recent news headlines are in the data, so no company-specific news context is available.